<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>Pasteur Institute of Iran</PublisherName>
				<JournalTitle>Iranian Biomedical Journal</JournalTitle>
				<Issn>2008-823X</Issn>
				<Volume>30</Volume>
				<Issue>3</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>04</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Resveratrol in Combination Therapy: Mechanisms and Limitations of Resveratrol in Cancer, Regeneration, and Chronic Disease</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>97</FirstPage>
			<LastPage>124</LastPage>
			<ELocationID EIdType="pii">740687</ELocationID>
			
<ELocationID EIdType="doi">10.61882/ibj.5210</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Effat</FirstName>
					<LastName>Noori</LastName>
<Affiliation>Department of Medical Biotechnology, Faculty of Medicine, Shahed University, Tehran, Iran</Affiliation>
<Identifier Source="ORCID">0000-0002-8196-1967</Identifier>

</Author>
<Author>
					<FirstName>Ramazan</FirstName>
					<LastName>Rezaei</LastName>
<Affiliation>Department of Immunology, Faculty of Medicine, Shahed University, Tehran, Iran</Affiliation>
<Identifier Source="ORCID">0000-0002-4504-7238</Identifier>

</Author>
<Author>
					<FirstName>Samira</FirstName>
					<LastName>Valiyari</LastName>
<Affiliation>Department of Medical Biotechnology, Faculty of Medicine, Shahed University, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Mahmood</FirstName>
					<LastName>Rekabgardan</LastName>
<Affiliation>Department  of Regenerative Medicine, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran;</Affiliation>
<Identifier Source="ORCID">0000-0002-0670-8021</Identifier>

</Author>
<Author>
					<FirstName>Parvin</FirstName>
					<LastName>Mohammadi</LastName>
<Affiliation>Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran</Affiliation>
<Identifier Source="ORCID">0000-0002-4724-8113</Identifier>

</Author>
<Author>
					<FirstName>Fatemeh</FirstName>
					<LastName>Soleymani</LastName>
<Affiliation>Department of Medical Biotechnology, Faculty of Medicine, Shahed University, Tehran, Iran</Affiliation>
<Identifier Source="ORCID">0009-0003-7081-2899</Identifier>

</Author>
<Author>
					<FirstName>Elham</FirstName>
					<LastName>Sharif</LastName>
<Affiliation>Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran</Affiliation>
<Identifier Source="ORCID">0000-0001-5559-2048</Identifier>

</Author>
<Author>
					<FirstName>Zohreh</FirstName>
					<LastName>Jafari</LastName>
<Affiliation>Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran;</Affiliation>
<Identifier Source="ORCID">0000-0002-1532-576X</Identifier>

</Author>
<Author>
					<FirstName>Delsuz</FirstName>
					<LastName>Rezaee</LastName>
<Affiliation>Department of Genetic and Molecular Medicine, School of Allied Medical Sciences, Ilam University of Medical Sciences, Ilam, Iran</Affiliation>
<Identifier Source="ORCID">0000-0001-9547-3211</Identifier>

</Author>
<Author>
					<FirstName>Fatemeh</FirstName>
					<LastName>Hajighasemi</LastName>
<Affiliation>Department of Immunology, Faculty of Medicine, Shahed University, Tehran, Iran;</Affiliation>
<Identifier Source="ORCID">0000-0003-0145-4621</Identifier>

</Author>
<Author>
					<FirstName>Forough</FirstName>
					<LastName>Shams*</LastName>
<Affiliation>Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran</Affiliation>
<Identifier Source="ORCID">0000-0001-5862-2679</Identifier>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2026</Year>
					<Month>08</Month>
					<Day>25</Day>
				</PubDate>
			</History>
		<Abstract>&lt;span&gt;&lt;span&gt;&lt;span&gt;Resveratrol (RSV), a nonflavonoid polyphenol phytoalexin, has considerable therapeutic potential for managing chronic and acute diseases due to its anti-inflammatory, anti-cancer, antimicrobial, and antioxidant properties. It can help protect cells from free radical damage and modulate signaling pathways in the body to promote overall health.  RSV can also facilitate the therapeutic effects of mesenchymal stem cells by increasing their self-renewal, survival, anti-aging effects, and lineage commitment. However, the natural form of RSV has limitations, such as poor intestinal absorption and low bioavailability. This review focuses on the potential of RSV to explore its effects and mechanisms of action in cancer, regenerative medicine, and chronic disease. It also discusses how RSV can protect normal tissue against genomic instability and presents findings from combination therapies involving RSV and nanoparticle-based agents. Overall, this review highlights the latest developments regarding RSV as a promising compound, emphasizing the potential to overcome its limitations.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">nanoparticles</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Regenerative medicine</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Resveratrol</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://ibj.pasteur.ac.ir/article_740687_7270e4c01c129862910cdeea71f74b2d.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Pasteur Institute of Iran</PublisherName>
				<JournalTitle>Iranian Biomedical Journal</JournalTitle>
				<Issn>2008-823X</Issn>
				<Volume>30</Volume>
				<Issue>3</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>04</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Global Perspectives on Rabies Prevention and Control: A Decade of World Rabies Day Themes and Progress toward Elimination (2016–2025)</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>125</FirstPage>
			<LastPage>131</LastPage>
			<ELocationID EIdType="pii">740688</ELocationID>
			
<ELocationID EIdType="doi">10.61882/ibj.5398</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Ashkan</FirstName>
					<LastName>Alamdary</LastName>
<Affiliation>Research and Development Department, Production and Research Complex,  Pasteur Institute of Iran, Karaj, Iran;</Affiliation>
<Identifier Source="ORCID">0000-0001-7776-8809</Identifier>

</Author>
<Author>
					<FirstName>Mehdi</FirstName>
					<LastName>Ajorloo</LastName>
<Affiliation>Biological Products and Blood Safety Research  Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Alireza</FirstName>
					<LastName>Gholami</LastName>
<Affiliation>Research and Development Department, Production and Research Complex,  Pasteur Institute of Iran, Karaj, Iran;</Affiliation>
<Identifier Source="ORCID">0000-0003-0706-2821</Identifier>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2026</Year>
					<Month>08</Month>
					<Day>25</Day>
				</PubDate>
			</History>
		<Abstract>&lt;span&gt;&lt;span&gt;&lt;span&gt;Rabies is a fatal zoonotic disease, responsible for approximately 59,000 human deaths annually; the majority occur in developing regions of Asia and Africa. This review explores worldwide efforts to prevent and control rabies during 2016–2025, using the evolving themes of World Rabies Day (WRD) as a framework. The research objective is to assess epidemiological trends, intervention strategies, challenges, and innovations related to the World Health Organization&#039;s target of zero human rabies deaths by 2030. The findings highlight a significant reduction in global rabies occurrence, with mass vaccination campaigns for dogs achieving 70% coverage in Guinea and a 95% decrease in human cases in Latin America. However, gaps in surveillance, vaccine shortages, and poor public education persist. Low-cost intradermal prophylaxis, monoclonal antibodies, and AI-driven surveillance systems are promising approaches but remain constrained by socioeconomic inequalities and insufficient investment. Achieving “Zero by 30” requires stronger collaboration, equitable resource distribution, and sustained community mobilization. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">One Health</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Post-exposure prophylaxis</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Rabies</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">zoonoses</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://ibj.pasteur.ac.ir/article_740688_3c80206ff30b62c56c2d46268b9f4fcc.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Pasteur Institute of Iran</PublisherName>
				<JournalTitle>Iranian Biomedical Journal</JournalTitle>
				<Issn>2008-823X</Issn>
				<Volume>30</Volume>
				<Issue>3</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>04</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Therapeutic Effects of Vernonia amygdalina on Oxidative Stress and Histopathological Damage in Pancreatic Toxicity Induced by 1,2-dimethylhydrazine in Wistar Rats</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>132</FirstPage>
			<LastPage>140</LastPage>
			<ELocationID EIdType="pii">740689</ELocationID>
			
<ELocationID EIdType="doi">10.61882/ibj.5354</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Augustine</FirstName>
					<LastName>Okpiabhele</LastName>
<Affiliation>Department of Biochemistry, Faculty of Natural and Applied Sciences, Michael and  Cecilia Ibru University, Ughelli, Delta State, Nigeria;</Affiliation>
<Identifier Source="ORCID">0000-0002-2552-2732</Identifier>

</Author>
<Author>
					<FirstName>Osahon</FirstName>
					<LastName>Abu</LastName>
<Affiliation>Department of Biochemistry,  Faculty of Life Sciences, University of Benin, Benin City, Edo State, Nigeria</Affiliation>
<Identifier Source="ORCID">0000-0002-8007-2199</Identifier>

</Author>
<Author>
					<FirstName>Ambrose</FirstName>
					<LastName>Akpovona</LastName>
<Affiliation>Department of Biochemistry, Faculty of Natural and Applied Sciences, Michael and  Cecilia Ibru University, Ughelli, Delta State, Nigeria;</Affiliation>
<Identifier Source="ORCID">0000-0003-1255-9250</Identifier>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2026</Year>
					<Month>08</Month>
					<Day>25</Day>
				</PubDate>
			</History>
		<Abstract>&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Background:&lt;/span&gt;&lt;span&gt; 1,2-Dimethylhydrazine (DMH) induces pancreatic oxidative stress via reactive oxygen species overproduction and antioxidant depletion. Given the rich phytochemical and antioxidant properties of Vernonia amygdalina, this study investigated its therapeutic effects in inhibiting oxidative stress and histopathological damage induced by DMH in Wistar rats.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span&gt;&lt;span&gt;&lt;span&gt;Methods: &lt;/span&gt;&lt;span&gt;Adult male Wistar rats were divided into different groups and exposed to DMH via the intraperitoneal route. Animals received oral administration of V. amygdalina ethanol extract at low (200 mg/kg) and high (400 mg/kg) doses, both before and after DMH exposure. The pancreatic tissues were then subjected to bio&lt;/span&gt;&lt;span&gt;chemical analysis and histopathological examination using standardized protocols.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span&gt;&lt;span&gt;&lt;span&gt;Results: &lt;/span&gt;&lt;span&gt;The administration of V. amygdalina significantly attenuated body weight loss in both the pre- and post-treatment groups. Furthermore, it significantly improved (p &lt; 0.05) the levels of total protein, amylase, nitric oxide, catalase, superoxide dismutase, malondialdehyde, glutathione peroxidase, glutathione (GSH), and glutathione reductase and reduced GSH percentages compared to the DMH group. The pancreatic tissues from DMH-induced rats treated with V. amygdalina showed a significant reduction (p &lt; 0.05) in organ weight compared to the DMH group. Histological studies revealed the protective and regenerative effects of V. amygdalina on pancreatic tissues.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span&gt;&lt;span&gt;Conclusion: &lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt;This study indicates that V. amygdalina can effectively suppress irregularities in pancreatic function and oxidative stress induced by DMH toxicity due to its antioxidant properties. This observation implies that V. amygdalina holds promise as a novel therapeutic strategy for improving DMH systemic toxicity in animal models and could serve as a benchmark for future clinical trials.&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">antioxidants</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Pancreas</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Toxicity</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://ibj.pasteur.ac.ir/article_740689_32c10ba02271a387c00ccd8599db944b.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Pasteur Institute of Iran</PublisherName>
				<JournalTitle>Iranian Biomedical Journal</JournalTitle>
				<Issn>2008-823X</Issn>
				<Volume>30</Volume>
				<Issue>3</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>04</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Antidepressant Effects of L-Arginine and Its Role in Brain Energy Metabolism</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>141</FirstPage>
			<LastPage>152</LastPage>
			<ELocationID EIdType="pii">740690</ELocationID>
			
<ELocationID EIdType="doi">10.61882/ibj.5314</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Temuri</FirstName>
					<LastName>Mantashashvili</LastName>
<Affiliation>Department of Biology, Ivane Javakhishvili Tbilisi State University,  11th Building, University Street, 0186, Tbilisi, Georgia</Affiliation>
<Identifier Source="ORCID">0000-0002-9738-1027</Identifier>

</Author>
<Author>
					<FirstName>Luka</FirstName>
					<LastName>Nakaidze</LastName>
<Affiliation>Department of Biology, Ivane Javakhishvili Tbilisi State University,  11th Building, University Street, 0186, Tbilisi, Georgia</Affiliation>
<Identifier Source="ORCID">0009-0004-9396-397X</Identifier>

</Author>
<Author>
					<FirstName>Mariam</FirstName>
					<LastName>Shengelia</LastName>
<Affiliation>Department of Biology, Ivane Javakhishvili Tbilisi State University,  11th Building, University Street, 0186, Tbilisi, Georgia</Affiliation>
<Identifier Source="ORCID">0009-0001-1276-5030</Identifier>

</Author>
<Author>
					<FirstName>Nana</FirstName>
					<LastName>Koshoridze</LastName>
<Affiliation>Department of Biology, Ivane Javakhishvili Tbilisi State University,  11th Building, University Street, 0186, Tbilisi, Georgia</Affiliation>
<Identifier Source="ORCID">0000-0002-6856-174X</Identifier>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2026</Year>
					<Month>08</Month>
					<Day>25</Day>
				</PubDate>
			</History>
		<Abstract>&lt;span&gt;&lt;span&gt;&lt;span&gt;Background:&lt;/span&gt;&lt;span&gt; Mitochondrial dysfunction and impaired cellular energy metabolism are increasingly recognized as key contributing factors&lt;/span&gt; &lt;span&gt;in depression. This study evaluated the amino acid L-arginine as a potential agent for behavioral rescue and bioenergetic restoration using a corticosterone-induced rat model of depression.&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span&gt;&lt;span&gt;&lt;span&gt;Methods:&lt;/span&gt; &lt;span&gt;Male rats were randomly assigned to four groups (n = 10): control (DMSO intraperitoneally [i.p.] + water oral gavage), corticosterone-induced depression (20 mg/kg, i.p. for 14 days), L-arginine treatment (150 mg/kg, oral gavage for 14 days), and fluoxetine (10 mg/kg, oral gavage for 14 days). To ensure handling equivalence, all oral administrations were performed via gavage (1.0 mL/100 g). Behavioral rescue was assessed via open field, forced swim (FST), and tail suspension (TST) tests. Hippocampal energy metabolism and PI3K/Akt/mTOR pathway activation were analyzed.&lt;/span&gt;&lt;span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span&gt;&lt;span&gt;&lt;span&gt;Results:&lt;/span&gt;&lt;span&gt;  L-arginine significantly improved the hippocampal bioenergetic profile, demonstrating efficacy comparable to the positive control fluoxetine. It led to a significant reduction in immobility time during FST and TST, alongside restoring glycolysis, the tricarboxylic acid cycle, and mitochondrial respiratory chain activities. Concurrently, L-arginine enhanced the activation state of the PI3K/Akt/mTOR signaling pathway (&lt;/span&gt;&lt;span&gt;phosphorylated Akt/Akt and p-mTOR/mTOR ratios) and improved the functional state of the mitochondrial permeability transition pore. These metabolic and signaling improvements strongly correlated with the rescue of depressive-like behaviors.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span&gt;&lt;span&gt;Conclusion:&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt; Our findings demonstrate that L-arginine possesses potent antidepressant-like potential, mediated through bioenergetic restoration and signaling pathway modulation. By activating key metabolic processes in the hippocampus, L-arginine effectively restores impaired cellular energy homeostasis, suggesting its promise as a metabolic modulator for alleviating neurobiological disturbances associated with depressive conditions. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Arginine</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Corticosterone</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Depression</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Energy metabolism</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Hippocampus</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://ibj.pasteur.ac.ir/article_740690_9427afcb5941c8b2c4899253b0c9bf8f.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Pasteur Institute of Iran</PublisherName>
				<JournalTitle>Iranian Biomedical Journal</JournalTitle>
				<Issn>2008-823X</Issn>
				<Volume>30</Volume>
				<Issue>3</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>04</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Molecular Characterization of Multi-Drug Resistant Histamine-Producing Gram-Negative Bacteria Isolated from Fermented Prosopis africana Seeds (okpee) in Nigeria</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>153</FirstPage>
			<LastPage>164</LastPage>
			<ELocationID EIdType="pii">740691</ELocationID>
			
<ELocationID EIdType="doi">10.61882/ibj.5259</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Cyril</FirstName>
					<LastName>Adonu</LastName>
<Affiliation>Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, Enugu State University of Science and Technology, Enugu State, Nigeria</Affiliation>
<Identifier Source="ORCID">0000-0002-3486-8137</Identifier>

</Author>
<Author>
					<FirstName>Sunday</FirstName>
					<LastName>Urama</LastName>
<Affiliation>Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, Enugu State University of Science and Technology, Enugu State, Nigeria</Affiliation>
<Identifier Source="ORCID">0009-0002-3691-5897</Identifier>

</Author>
<Author>
					<FirstName>Abugu</FirstName>
					<LastName>Felix</LastName>
<Affiliation>Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, Enugu State University of Science and Technology, Enugu State, Nigeria</Affiliation>
<Identifier Source="ORCID">0009-0000-3593-6667</Identifier>

</Author>
<Author>
					<FirstName>Eze</FirstName>
					<LastName>Victor</LastName>
<Affiliation>Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, Enugu State University of Science and Technology, Enugu State, Nigeria</Affiliation>
<Identifier Source="ORCID">0009-0002-6866-8931</Identifier>

</Author>
<Author>
					<FirstName>Treasure</FirstName>
					<LastName>Ujam</LastName>
<Affiliation>Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, Enugu State University of Science and Technology, Enugu State, Nigeria</Affiliation>
<Identifier Source="ORCID">0000-0002-8523-3086</Identifier>

</Author>
<Author>
					<FirstName>Gospel</FirstName>
					<LastName>OKpara</LastName>
<Affiliation>Department of Pharmaceutical Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, Enugu State University of Science and Technology, Enugu State, Nigeria</Affiliation>
<Identifier Source="ORCID">0009-0007-8987-2428</Identifier>

</Author>
<Author>
					<FirstName>Hannah</FirstName>
					<LastName>Okorie</LastName>
<Affiliation>Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Enugu State University of Science and Technology, Enugu State, Nigeria</Affiliation>
<Identifier Source="ORCID">0000-0003-4477-3972</Identifier>

</Author>
<Author>
					<FirstName>Eucharia</FirstName>
					<LastName>Imanyika</LastName>
<Affiliation>Department of Medical Microbiology, College of Medicine, Enugu State University of Science and Technology, Enugu State, Nigeria</Affiliation>
<Identifier Source="ORCID">0000-0002-8611-8952</Identifier>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2026</Year>
					<Month>08</Month>
					<Day>25</Day>
				</PubDate>
			</History>
		<Abstract>&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Background: Fermented Prosopis africana seeds (okpee) are naturally protein-rich but exude odors that attract houseflies. These flies can carry contaminants, including pathogens and histamine-producing bacteria. Bacterial histamine in food can cause illnesses and pseudo-hypersensitivity reactions. This study investigated multidrug-resistant, histamine-producing Gram-negative bacteria (GNB) isolated from okpee sold in Enugu Ezike, Nigeria.&lt;/span&gt;&lt;br&gt;
&lt;span&gt;&lt;span&gt;&lt;span&gt;Methods: &lt;/span&gt;&lt;/span&gt;Histamine content of the mesquite seed samples was determined using high-performance liquid chromatography. Bacteriological isolates from randomly sampled okpee were identified by 16S rRNA gene sequencing. Antibiotic susceptibility of the isolated bacteria was assessed using the Kirby-Bauer disk agar diffusion method. The isolates were also screened for resistant plasmids and virulence genes (Stx2 and toxA). &lt;/span&gt;&lt;br&gt;
&lt;span&gt;Results: Histamine levels of the fermented samples averaged 1.0 × 10&lt;sup&gt;-4&lt;/sup&gt;-6.2 × 10&lt;sup&gt;-1&lt;/sup&gt; mg/kg. Of 240 samples of okpee screened, 25 (10.5%) were contaminated with histamine-producing GNB, including Pseudomonas spp., Escherichia coli, E. fergusonii, and Shigella flexneri. All the isolated histamine-producing bacteria were resistant to amoxicillin, erythromycin, ampicillin, and cefuroxime, with more than 50% exhibiting resistance to the other antibiotics tested. The test isolates were found to harbor multiple resistant plasmids (size: 0.5 kbp-10 kbp) and virulence factor genes Stx2 and toxA.&lt;/span&gt;&lt;br&gt;
&lt;span&gt;Conclusion: This study observed a high prevalence of bacterial contaminants capable of producing histamine in okpee sold in Enugu Ezike, Nigeria. The isolates were multidrug-resistant and harbored virulent genes, posing a serious public health risk. Therefore, strengthening hygiene practices during the production and handling of okpee is necessary to prevent contamination and ensure product safety.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Fermentation</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Gram-negative bacteria</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">histamine</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Virulence Factors</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://ibj.pasteur.ac.ir/article_740691_5538a53a9677d7a0ad0569abbadfb646.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Pasteur Institute of Iran</PublisherName>
				<JournalTitle>Iranian Biomedical Journal</JournalTitle>
				<Issn>2008-823X</Issn>
				<Volume>30</Volume>
				<Issue>3</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>04</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Antiviral Potential of Lipopeptide Biosurfactant Isolated from Acinetobacter junii B6</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>165</FirstPage>
			<LastPage>173</LastPage>
			<ELocationID EIdType="pii">740692</ELocationID>
			
<ELocationID EIdType="doi">10.61882/ibj.5241</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Amir Mohammad</FirstName>
					<LastName>Bagheri</LastName>
<Affiliation>Herbal and Traditional Medicines Research Center, Institute of Pharmaceutical Sciences, Kerman  University of Medical Sciences, Kerman, Iran</Affiliation>
<Identifier Source="ORCID">0000-0002-7375-4888</Identifier>

</Author>
<Author>
					<FirstName>Hamid</FirstName>
					<LastName>Forootanfar</LastName>
<Affiliation>Pharmaceutical Sciences and Cosmetic Products  Research Center, Institute of Pharmaceutical Sciences, Kerman University of Medical Sciences, Kerman,  Iran</Affiliation>
<Identifier Source="ORCID">0000-0001-5049-7674</Identifier>

</Author>
<Author>
					<FirstName>Gholamreza</FirstName>
					<LastName>Dehghannoudeh</LastName>
<Affiliation>Department of Pharmaceutics, Faculty of Pharmacy,  Kerman University of Medical Sciences, Kerman, Iran</Affiliation>
<Identifier Source="ORCID">0000-0003-1420-2650</Identifier>

</Author>
<Author>
					<FirstName>Mohammad Amin</FirstName>
					<LastName>Raeisi Estabragh</LastName>
<Affiliation>Department of Pharmaceutics, Faculty of Pharmacy,  Kerman University of Medical Sciences, Kerman, Iran</Affiliation>
<Identifier Source="ORCID">0000-0001-5992-1654</Identifier>

</Author>
<Author>
					<FirstName>Ibrahim</FirstName>
					<LastName>M. Banat</LastName>
<Affiliation>School of Biomedical Sciences, Faculty of Life &amp; Health Sciences, Ulster University, Coleraine BT52 1SA, N. Ireland, UK</Affiliation>
<Identifier Source="ORCID">0000-0001-8964-2840</Identifier>

</Author>
<Author>
					<FirstName>Hosnieh</FirstName>
					<LastName>Sokhandan</LastName>
<Affiliation>Influenza and Respiratory Viruses Department, Pasteur Institute of Iran,  Tehran, Iran</Affiliation>
<Identifier Source="ORCID">0009-0003-1750-2090</Identifier>

</Author>
<Author>
					<FirstName>Hadiseh</FirstName>
					<LastName>Shokouhi</LastName>
<Affiliation>Influenza and Respiratory Viruses Department, Pasteur Institute of Iran,  Tehran, Iran; 7Autophagy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran</Affiliation>
<Identifier Source="ORCID">0000-0002-4325-6554</Identifier>

</Author>
<Author>
					<FirstName>Mandana</FirstName>
					<LastName>Ohadi</LastName>
<Affiliation>Pharmaceutics Research Center, Institute of Pharmaceutical Sciences, Kerman University of Medical  Sciences, Kerman, Iran</Affiliation>
<Identifier Source="ORCID">0000-0001-7251-3751</Identifier>

</Author>
<Author>
					<FirstName>Parvaneh</FirstName>
					<LastName>Mehrbod*</LastName>
<Affiliation>Influenza and Respiratory Viruses Department, Pasteur Institute of Iran, Tehran, Iran</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2026</Year>
					<Month>08</Month>
					<Day>25</Day>
				</PubDate>
			</History>
		<Abstract>&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Background: &lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt;Influenza A virus (IAV) is a global health concern, increasing the exploration of alternative therapeutics. Biosurfactants (BSs) are biodegradable, non-toxic biomolecules with favorable biological activities. Acinetobacter junii B6, known for utilizing crude oil as a carbon and energy source, produces BSs. This study evaluated the antiviral potential of the lipopeptide biosurfactant (LPB) against H1N1/A/PR8/34 infection.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Methods&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt;: A. junii B6 LPB was extracted and characterized in our previous study. The 50% cytotoxic concentration and non-cytotoxic concentration (NCTC), defined as the concentration with no toxicity on cells, were determined by the MTT assay on MDCK cells. The NCTC was exposed to the cells in the presence of PR8 (100 TCID&lt;sub&gt;50&lt;/sub&gt;) under simultaneous, pre- and post-exposure combination treatments for 1 h. After 48 h of incubation, the hemagglutination and MTT assays assessed viral propagation and cell protection, respectively. Amantadine and oseltamivir served as antiviral control drugs.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Results: &lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt;The extracted LPB caused a 1 log&lt;sub&gt;2&lt;/sub&gt; reduction in pre- and post-exposure treatments, whereas amantadine &lt;/span&gt;and &lt;span&gt;oseltamivir &lt;/span&gt;reduced viral titers by more than 1 &lt;span&gt;log&lt;sub&gt;2&lt;/sub&gt;. Cell protection was favorable in all combination treatments&lt;/span&gt; except for LPB co-treatment&lt;span&gt;. LPB extract showed limited but notable anti-IAV activity, alongside cell protection.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span&gt;&lt;span&gt;&lt;span&gt;Conclusion: &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;While LPB is less potent than amantadine and oseltamivir, its non-toxic and environmentally friendly nature warrants further study. As surfactants act on the lipid envelope, viral proteins, and nucleocapsid proteins, LPB could be potentially used as an adjuvant with other antiviral agents to control the prevalence of viral diseases and improve therapeutic outcomes.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Acinetobacter junii</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Antiviral Agents</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Influenza A virus</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Lipopeptides</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://ibj.pasteur.ac.ir/article_740692_1231e8515d1877a015ad2222fb5734a7.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Pasteur Institute of Iran</PublisherName>
				<JournalTitle>Iranian Biomedical Journal</JournalTitle>
				<Issn>2008-823X</Issn>
				<Volume>30</Volume>
				<Issue>3</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>04</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Clonal Diversity and Genetic Landscape of mecC-Positive S. aureus in Human Samples from Iran: First Report of CC/ST423/t742</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>174</FirstPage>
			<LastPage>187</LastPage>
			<ELocationID EIdType="pii">740693</ELocationID>
			
<ELocationID EIdType="doi">10.61882/ibj.5161</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Mehdi</FirstName>
					<LastName>Goudarzi</LastName>
<Affiliation>Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran</Affiliation>
<Identifier Source="ORCID">0000-0001-6720-9341</Identifier>

</Author>
<Author>
					<FirstName>Sima Sadat</FirstName>
					<LastName>Seyedjavadi</LastName>
<Affiliation>Department of Mycology, Pasteur Institute of Iran, Tehran, Iran</Affiliation>
<Identifier Source="ORCID">0000-0002-5896-5636</Identifier>

</Author>
<Author>
					<FirstName>Mozhgan</FirstName>
					<LastName>Raigani</LastName>
<Affiliation>Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran</Affiliation>
<Identifier Source="ORCID">0000-0003-4764-0606</Identifier>

</Author>
<Author>
					<FirstName>Zahra</FirstName>
					<LastName>Salehi</LastName>
<Affiliation>Department of Mycology, Pasteur Institute of Iran, Tehran, Iran</Affiliation>
<Identifier Source="ORCID">0000-0002-4913-6211</Identifier>

</Author>
<Author>
					<FirstName>Masoud</FirstName>
					<LastName>Dadashi</LastName>
<Affiliation>Department of Microbiology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran</Affiliation>
<Identifier Source="ORCID">0000-0002-4800-2078</Identifier>

</Author>
<Author>
					<FirstName>Mohammad Javad</FirstName>
					<LastName>Nasiri</LastName>
<Affiliation>Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran</Affiliation>
<Identifier Source="ORCID">0000-0002-3279-0671</Identifier>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2026</Year>
					<Month>08</Month>
					<Day>25</Day>
				</PubDate>
			</History>
		<Abstract>&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Ba&lt;span&gt;c&lt;/span&gt;&lt;span&gt;k&lt;/span&gt;g&lt;span&gt;r&lt;/span&gt;o&lt;span&gt;un&lt;/span&gt;&lt;span&gt;d&lt;/span&gt;&lt;/span&gt;&lt;span&gt;: &lt;/span&gt;&lt;span&gt;The &lt;span&gt;e&lt;/span&gt;me&lt;span&gt;r&lt;/span&gt;g&lt;span&gt;e&lt;/span&gt;n&lt;span&gt;c&lt;/span&gt;e of &lt;span&gt;m&lt;/span&gt;&lt;span&gt;ec&lt;/span&gt;&lt;span&gt;C&lt;/span&gt;&lt;span&gt;-&lt;/span&gt;&lt;span&gt;ca&lt;/span&gt;&lt;span&gt;r&lt;/span&gt;rying Staphylococcus aur&lt;span&gt;e&lt;/span&gt;us str&lt;span&gt;a&lt;/span&gt;ins is a s&lt;span&gt;e&lt;/span&gt;rious &lt;span&gt;c&lt;/span&gt;on&lt;span&gt;ce&lt;/span&gt;rn in publ&lt;span&gt;i&lt;/span&gt;c h&lt;span&gt;ea&lt;/span&gt;l&lt;span&gt;t&lt;/span&gt;h. Our study investigated the clonal diversity, genetic characteristics, antimicrobial resistance, virulence determinants, biofilm-forming ability, and molecular epidemiology of mecC-positive Staphylococcus aureus isolates obtained from hospitalized patients in Iran.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Me&lt;/span&gt;tho&lt;span&gt;d&lt;/span&gt;s&lt;/span&gt;&lt;span&gt;: &lt;/span&gt;&lt;span&gt;&lt;span&gt;We analyzed &lt;/span&gt;45 m&lt;span&gt;ec&lt;/span&gt;&lt;span&gt;C&lt;/span&gt;&lt;span&gt;-&lt;/span&gt;&lt;span&gt;ca&lt;/span&gt;r&lt;span&gt;r&lt;/span&gt;ying S. aur&lt;span&gt;e&lt;/span&gt;us &lt;span&gt;strains &lt;/span&gt;isolated f&lt;span&gt;r&lt;/span&gt;om 1,590 S. au&lt;span&gt;r&lt;/span&gt;&lt;span&gt;e&lt;/span&gt;us samples collected from dif&lt;span&gt;f&lt;/span&gt;&lt;span&gt;e&lt;/span&gt;r&lt;span&gt;e&lt;/span&gt;nt &lt;span&gt;c&lt;/span&gt;l&lt;span&gt;i&lt;/span&gt;nic&lt;span&gt;a&lt;/span&gt;l sources.&lt;span&gt; The &lt;/span&gt;&lt;span&gt;c&lt;/span&gt;&lt;span&gt;h&lt;/span&gt;&lt;span&gt;a&lt;/span&gt;&lt;span&gt;r&lt;/span&gt;&lt;span&gt;ac&lt;/span&gt;te&lt;span&gt;r&lt;/span&gt;&lt;span&gt;i&lt;/span&gt;&lt;span&gt;za&lt;/span&gt;t&lt;span&gt;i&lt;/span&gt;on included &lt;span&gt;a&lt;/span&gt;nt&lt;span&gt;i&lt;/span&gt;m&lt;span&gt;i&lt;/span&gt;&lt;span&gt;c&lt;/span&gt;robi&lt;span&gt;a&lt;/span&gt;l susc&lt;span&gt;e&lt;/span&gt;pt&lt;span&gt;i&lt;/span&gt;bi&lt;span&gt;l&lt;/span&gt;i&lt;span&gt;t&lt;/span&gt;y tests, assessment of biof&lt;span&gt;il&lt;/span&gt;m fo&lt;span&gt;r&lt;/span&gt;mation, spa typ&lt;span&gt;i&lt;/span&gt;ng, mu&lt;span&gt;l&lt;/span&gt;t&lt;span&gt;i&lt;/span&gt;locus s&lt;span&gt;e&lt;/span&gt;qu&lt;span&gt;e&lt;/span&gt;n&lt;span&gt;c&lt;/span&gt;e typ&lt;span&gt;i&lt;/span&gt;ng (M&lt;span&gt;L&lt;/span&gt;&lt;span&gt;S&lt;/span&gt;T&lt;span&gt;)&lt;/span&gt;, &lt;span&gt;a&lt;/span&gt;nd &lt;span&gt;P&lt;/span&gt;CR &lt;span&gt;a&lt;/span&gt;n&lt;span&gt;a&lt;/span&gt;lys&lt;span&gt;i&lt;/span&gt;s&lt;span&gt; to &lt;/span&gt;d&lt;span&gt;e&lt;/span&gt;t&lt;span&gt;e&lt;/span&gt;&lt;span&gt;c&lt;/span&gt;t r&lt;span&gt;e&lt;/span&gt;&lt;span&gt;s&lt;/span&gt;is&lt;span&gt;t&lt;/span&gt;&lt;span&gt;a&lt;/span&gt;n&lt;span&gt;c&lt;/span&gt;e, biofi&lt;span&gt;l&lt;/span&gt;m-related, &lt;span&gt;a&lt;/span&gt;nd virul&lt;span&gt;e&lt;/span&gt;n&lt;span&gt;c&lt;/span&gt;e g&lt;span&gt;e&lt;/span&gt;n&lt;span&gt;e&lt;/span&gt;s.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span&gt;&lt;span&gt;&lt;span&gt;R&lt;span&gt;e&lt;/span&gt;s&lt;span&gt;u&lt;/span&gt;lts: &lt;/span&gt;&lt;span&gt;Our &lt;span&gt;r&lt;/span&gt;&lt;span&gt;e&lt;/span&gt;sul&lt;span&gt;t&lt;/span&gt;s show&lt;span&gt;e&lt;/span&gt;d that 17.&lt;span&gt;8&lt;/span&gt;&lt;span&gt;%&lt;/span&gt;, 17.8&lt;span&gt;%&lt;/span&gt;, &lt;span&gt;a&lt;/span&gt;nd 64.4% of the iso&lt;span&gt;l&lt;/span&gt;&lt;span&gt;a&lt;/span&gt;tes &lt;span&gt;w&lt;/span&gt;&lt;span&gt;e&lt;/span&gt;re &lt;span&gt;c&lt;/span&gt;lassifi&lt;span&gt;e&lt;/span&gt;d &lt;span&gt;a&lt;/span&gt;s w&lt;span&gt;ea&lt;/span&gt;k, in&lt;span&gt;t&lt;/span&gt;&lt;span&gt;e&lt;/span&gt;rm&lt;span&gt;e&lt;/span&gt;diat&lt;span&gt;e&lt;/span&gt;, &lt;span&gt;a&lt;/span&gt;nd strong biofi&lt;span&gt;l&lt;/span&gt;m prod&lt;span&gt;uce&lt;/span&gt;rs, respectively. The pr&lt;span&gt;e&lt;/span&gt;v&lt;span&gt;a&lt;/span&gt;len&lt;span&gt;c&lt;/span&gt;e of&lt;span&gt; the &lt;/span&gt;ant(4&lt;span&gt;΄&lt;/span&gt;&lt;span&gt;)&lt;/span&gt;&lt;span&gt;-&lt;/span&gt;Ia and te&lt;span&gt;t&lt;/span&gt;(M) &lt;span&gt;was&lt;/span&gt; found in 80&lt;span&gt;% and &lt;/span&gt;73.&lt;span&gt;3&lt;/span&gt;&lt;span&gt;% of the isolates, respectively. &lt;/span&gt;ML&lt;span&gt;S&lt;/span&gt;T r&lt;span&gt;e&lt;/span&gt;v&lt;span&gt;e&lt;/span&gt;&lt;span&gt;a&lt;/span&gt;led that the 45 iso&lt;span&gt;l&lt;/span&gt;&lt;span&gt;a&lt;/span&gt;tes&lt;span&gt; b&lt;/span&gt;&lt;span&gt;e&lt;/span&gt;longed to four&lt;span&gt; clonal complexes:&lt;/span&gt; &lt;span&gt;C&lt;/span&gt;C8 (44.&lt;span&gt;4%&lt;/span&gt;), CC130 (24&lt;span&gt;.&lt;/span&gt;5&lt;span&gt;%&lt;/span&gt;), CC121 (17.&lt;span&gt;8%&lt;/span&gt;), &lt;span&gt;a&lt;/span&gt;nd CC425 (13.&lt;span&gt;3%&lt;/span&gt;&lt;span&gt;)&lt;/span&gt;. The majo&lt;span&gt;r&lt;/span&gt;i&lt;span&gt;t&lt;/span&gt;y of S. aur&lt;span&gt;e&lt;/span&gt;us iso&lt;span&gt;l&lt;/span&gt;&lt;span&gt;a&lt;/span&gt;tes b&lt;span&gt;e&lt;/span&gt;longed to&lt;span&gt; the &lt;/span&gt;&lt;span&gt;C&lt;/span&gt;C8/&lt;span&gt;S&lt;/span&gt;T239 lineage (44.&lt;span&gt;4%)&lt;/span&gt;. Also, ts&lt;span&gt;t&lt;/span&gt;-posit&lt;span&gt;i&lt;/span&gt;ve str&lt;span&gt;a&lt;/span&gt;ins belonged to &lt;span&gt;C&lt;/span&gt;C121/&lt;span&gt;S&lt;/span&gt;T599&lt;span&gt;/&lt;/span&gt;t5930 (17.&lt;span&gt;8%&lt;/span&gt;) &lt;span&gt;a&lt;/span&gt;nd CC8/&lt;span&gt;S&lt;/span&gt;T2&lt;span&gt;3&lt;/span&gt;9/&lt;span&gt;t&lt;/span&gt;037 (11.&lt;span&gt;1%&lt;/span&gt;), while &lt;span&gt;e&lt;/span&gt;t&lt;span&gt;a&lt;/span&gt;&lt;span&gt;-&lt;/span&gt;posit&lt;span&gt;i&lt;/span&gt;ve iso&lt;span&gt;l&lt;/span&gt;&lt;span&gt;a&lt;/span&gt;tes b&lt;span&gt;e&lt;/span&gt;l&lt;span&gt;o&lt;/span&gt;ng&lt;span&gt;e&lt;/span&gt;d to C&lt;span&gt;C&lt;/span&gt;/&lt;span&gt;S&lt;/span&gt;T130/&lt;span&gt;t&lt;/span&gt;843 (15.&lt;span&gt;6%&lt;/span&gt;&lt;span&gt;)&lt;/span&gt;. &lt;span&gt;F&lt;/span&gt;usid&lt;span&gt;i&lt;/span&gt;c &lt;span&gt;ac&lt;/span&gt;i&lt;span&gt;d&lt;/span&gt;&lt;span&gt;-&lt;/span&gt;&lt;span&gt;r&lt;/span&gt;&lt;span&gt;e&lt;/span&gt;si&lt;span&gt;s&lt;/span&gt;tant S. aur&lt;span&gt;e&lt;/span&gt;us &lt;span&gt;i&lt;/span&gt;solat&lt;span&gt;e&lt;/span&gt;s primarily b&lt;span&gt;e&lt;/span&gt;longed to CC8/&lt;span&gt;S&lt;/span&gt;T239&lt;span&gt;/&lt;/span&gt;t037&lt;span&gt; lineage &lt;/span&gt;(11.&lt;span&gt;1%&lt;/span&gt;&lt;span&gt;)&lt;/span&gt;, follow&lt;span&gt;e&lt;/span&gt;d by CC8/&lt;span&gt;S&lt;/span&gt;T239/&lt;span&gt;t&lt;/span&gt;7688 (6&lt;span&gt;.&lt;/span&gt;7&lt;span&gt;%&lt;/span&gt;),&lt;span&gt; both &lt;/span&gt;&lt;span&gt;c&lt;/span&gt;&lt;span&gt;a&lt;/span&gt;r&lt;span&gt;r&lt;/span&gt;ying the fus&lt;span&gt;B&lt;/span&gt;&lt;span&gt; gene&lt;/span&gt;. &lt;span&gt;V&lt;/span&gt;&lt;span&gt;a&lt;/span&gt;n&lt;span&gt;c&lt;/span&gt;omyci&lt;span&gt;n&lt;/span&gt;-in&lt;span&gt;t&lt;/span&gt;&lt;span&gt;e&lt;/span&gt;rm&lt;span&gt;e&lt;/span&gt;diate S. aur&lt;span&gt;e&lt;/span&gt;us st&lt;span&gt;r&lt;/span&gt;&lt;span&gt;a&lt;/span&gt;ins were classified into CC/&lt;span&gt;S&lt;/span&gt;T599/&lt;span&gt;t&lt;/span&gt;5930 &lt;span&gt;(&lt;/span&gt;6.7%) &lt;span&gt;a&lt;/span&gt;nd CC/&lt;span&gt;S&lt;/span&gt;T130/&lt;span&gt;t&lt;/span&gt;843 (4.4%)&lt;span&gt; c&lt;/span&gt;lo&lt;span&gt;n&lt;/span&gt;&lt;span&gt;e&lt;/span&gt;s.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span&gt;&lt;span&gt;&lt;span&gt;Concl&lt;span&gt;u&lt;/span&gt;sio&lt;span&gt;n&lt;/span&gt;: &lt;/span&gt;&lt;span&gt;This study &lt;span&gt;h&lt;/span&gt;igh&lt;span&gt;l&lt;/span&gt;igh&lt;span&gt;t&lt;/span&gt;s the need for close and continuous monitoring of the g&lt;span&gt;e&lt;/span&gt;n&lt;span&gt;e&lt;/span&gt;t&lt;span&gt;i&lt;/span&gt;c di&lt;span&gt;v&lt;/span&gt;&lt;span&gt;e&lt;/span&gt;rsity &lt;span&gt;a&lt;/span&gt;nd &lt;span&gt;c&lt;/span&gt;h&lt;span&gt;a&lt;/span&gt;&lt;span&gt;r&lt;/span&gt;&lt;span&gt;ac&lt;/span&gt;t&lt;span&gt;e&lt;/span&gt;rist&lt;span&gt;i&lt;/span&gt;&lt;span&gt;c&lt;/span&gt;s of the m&lt;span&gt;e&lt;/span&gt;&lt;span&gt;c&lt;/span&gt;&lt;span&gt;C&lt;/span&gt;&lt;span&gt;-c&lt;/span&gt;&lt;span&gt;a&lt;/span&gt;r&lt;span&gt;r&lt;/span&gt;ying S. aur&lt;span&gt;e&lt;/span&gt;us str&lt;span&gt;a&lt;/span&gt;ins. B&lt;span&gt;e&lt;/span&gt;sid&lt;span&gt;e&lt;/span&gt;s, urgent me&lt;span&gt;a&lt;/span&gt;sur&lt;span&gt;e&lt;/span&gt;s are required to &lt;span&gt;p&lt;/span&gt;r&lt;span&gt;e&lt;/span&gt;v&lt;span&gt;e&lt;/span&gt;nt t&lt;span&gt;h&lt;/span&gt;e tr&lt;span&gt;a&lt;/span&gt;nsm&lt;span&gt;i&lt;/span&gt;ss&lt;span&gt;i&lt;/span&gt;on of these strains and to effectively tr&lt;span&gt;e&lt;/span&gt;&lt;span&gt;a&lt;/span&gt;t associated inf&lt;span&gt;ec&lt;/span&gt;t&lt;span&gt;i&lt;/span&gt;ons. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Hospitals</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Methicillin-Resistant Staphylococcus aureus</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Staphylococcus aureus</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://ibj.pasteur.ac.ir/article_740693_f20c4f10ddd52ef71654dedc7683b846.pdf</ArchiveCopySource>
</Article>

<Article>
<Journal>
				<PublisherName>Pasteur Institute of Iran</PublisherName>
				<JournalTitle>Iranian Biomedical Journal</JournalTitle>
				<Issn>2008-823X</Issn>
				<Volume>30</Volume>
				<Issue>3</Issue>
				<PubDate PubStatus="epublish">
					<Year>2026</Year>
					<Month>04</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Whole-Exome Sequencing Identified a Novel Mutation in an Iranian Patient with Epidermolysis Bullosa</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>188</FirstPage>
			<LastPage>192</LastPage>
			<ELocationID EIdType="pii">740694</ELocationID>
			
<ELocationID EIdType="doi">10.61882/ibj.5232</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Reza</FirstName>
					<LastName>Mirfakhraie</LastName>
<Affiliation>Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran,  Iran</Affiliation>
<Identifier Source="ORCID">0000-0003-1709-8975</Identifier>

</Author>
<Author>
					<FirstName>Solmaz</FirstName>
					<LastName>Hassani Fard Katiraei</LastName>
<Affiliation>Department of Medical Genetics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran</Affiliation>
<Identifier Source="ORCID">0009-0008-4691-0997</Identifier>

</Author>
<Author>
					<FirstName>Mina</FirstName>
					<LastName>Mirnezami</LastName>
<Affiliation>Department of Dermatology, School of Medicine, Arak University of Medical Sciences, Arak, Iran</Affiliation>
<Identifier Source="ORCID">0000-0001-9423-004X</Identifier>

</Author>
<Author>
					<FirstName>Sahar</FirstName>
					<LastName>Bayat</LastName>
<Affiliation>Department  of Biochemistry and Genetics, School of Medicine, Arak University of Medical Sciences, Arak, Iran</Affiliation>
<Identifier Source="ORCID">0000-0002-2066-183X</Identifier>

</Author>
<Author>
					<FirstName>Mohsen</FirstName>
					<LastName>Soosanabadi</LastName>
<Affiliation>Department  of Medical Genetics, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran</Affiliation>
<Identifier Source="ORCID">0000-0002-9359-9782</Identifier>

</Author>
<Author>
					<FirstName>Ali</FirstName>
					<LastName>Kookhaei</LastName>
<Affiliation>Department of Dermatology, School of Medicine, Arak University of Medical Sciences, Arak, Iran</Affiliation>
<Identifier Source="ORCID">0009-0001-0901-4041</Identifier>

</Author>
<Author>
					<FirstName>Milad</FirstName>
					<LastName>Gholami</LastName>
<Affiliation>Department  of Biochemistry and Genetics, School of Medicine, Arak University of Medical Sciences, Arak, Iran</Affiliation>
<Identifier Source="ORCID">0000-0002-7201-8301</Identifier>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2026</Year>
					<Month>08</Month>
					<Day>25</Day>
				</PubDate>
			</History>
		<Abstract>&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Background:&lt;/span&gt;&lt;span&gt; Epidermolysis bullosa (EB) is a rare, genetically heterogeneous disorder characterized by skin fragility. EB is categorized into four types: simplex, junctional, dystrophic, and Kindler syndromes. The condition is caused by mutations in several genes that are important for skin integrity and dermal-epidermal adhesion. In the present study, we recruited a patient with EB from an Iranian pedigree for genetic evaluation.&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span&gt;&lt;span&gt;Methods:&lt;/span&gt;&lt;span&gt; Whole-exome sequencing (WES) and bioinformatics analysis were performed using genomic DNA from the patient with EB. The potential variant was confirmed by Sanger sequencing.&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span&gt;&lt;span&gt;Results:&lt;/span&gt; &lt;span&gt;We identified a novel likely pathogenic variant in exon 3 of the COL17A1 gene: c.82dup (&lt;/span&gt;&lt;span&gt;p.Thr28Asnfs15&lt;/span&gt;&lt;span&gt;). The patient’s parents were heterozygous carriers of this mutation. In silico structural prediction suggested that this variant could cause premature termination of COL17A1. This variant is associated with intermediate junctional EB-4 (JEB4).&lt;span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span&gt;&lt;span&gt;&lt;span&gt;Conclusion: &lt;/span&gt;&lt;span&gt;This study highlights that WES enhances our understanding of genetic diagnosis, and it contributes to the expanded mutational spectrum of the COL17A1 gene associated with JEB.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
 &lt;/span&gt;</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">epidermolysis bullosa</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Exome sequencing</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Mutation</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://ibj.pasteur.ac.ir/article_740694_a6eecfc83f7acc3a8316ed458f72d914.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
